Attendee search 

We have, by a wide margin, the safest and most effective nocturia drug. Nocturia leads to over 10,000 deaths per day and costs the US economy $215B/year in lost worktime and lower productivity.  We have the only drug that treats low bladder capacity, which is an issue for 76% of nocturia sufferers.  Our clinical trial results were 5x better than the first FDA approved nocturia drug and 2.5x better than the other FDA approved nocturia drug, both of which carry a black warning about a dangerous blood disorder and have other side effects.  Of course these drugs treat polyuria rather than low bladder capacity, so they are not competitors for our drug.

pharmaceutical company

OniX invest in companies in two ways: (1) Directly through it OniX Venture Fund and (2) Indirectly through its OniX hub members (includes pharma, VC, PE, family offices and private foundations)

Henlius (2696.HK) is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative biologics for patients worldwide with a focus on oncology and autoimmune diseases. Since its inception in 2010, Henlius has built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California, and commercial office in Frankfurt. The three R&D centers closely collaborate with each other to ensure a highly productive and cost-efficient R&D process.
Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. Henlius establishes a diversified product pipeline of biosimilars, bio-innovative drugs and combination therapies, and builds an integrated platform covering the whole product lifecycle including R&D, commercial-scale production and commercialization.

Keywords : Cancer, Oncology, Biologics, Biosimilar, BioInnovative, Biobetter, Monoclonal Antibody, Mabs, Tumors, Immuno oncology, PD1, PD-L1, EGFR, VEGF, HER2,

Trading in Pharmaceuticals and Medical Devices and Medical consumable products in United Arab Emirated

Phagelux is creating novel and best in class biological skin sciences products.

Medical platform who has got a medical application named Congo medika (available on Google playstore) that offer 3 services :medical home care, home delivery of drug and useful health advices

Pleiogenix is a clinical-stage bio-pharmaceutical company that will develop safe and effective treatments for liver and other diseases with significant unmet medical needs. The initial disease that Pleiogenix is targeting is alcoholic hepatitis (AH), with additional diseases to follow (COVID-19, Fibrosis, and NASH) . AH is a deadly liver disease resulting in mortality in most patients within 6 months, in the absence of a liver transplant. The global and US prevalence is 20-25%. The AH market is estimated to be $1.2 Billion in 2025, having a current annual growth rate of 6% (2019-2025). There are no approved efficacious therapeutics for the prevention or treatment of AH (dexamethasone reduces inflammation). The target patients for therapy include those with moderate and severe forms of AH. Pleiogenix has identified a Phase 2A-ready drug candidate, PLG888, an orally available, pan-PPAR agonist (non-thiazolidinedione) that increases circulating adiponectin without eliciting body weight gain or edema. Adiponectin is a hormone possessing significant anti-inflammatory, anti-fibrotic, and multiple metabolic clinical benefits. In patients suffering from AH, inflammation is severely increased. In animal models of NASH, increased adiponectin is linked to decreased systemic inflammation, increased hepatic fat oxidation, decreased hepatic fibrosis, and amelioration of NASH. Thus, PLG888 has the potential to become the first prescription pharmaceutical that exhibits multiple beneficial effects, in the context of AH.